text stringlengths 1 17.8k |
|---|
肽类激素、生长因子和相关物质 禁用下列物质及其释放因子： 1． 促进红血球生成的药剂（例如 erythropoietin 促红细胞生成素 /（EPO）, darbepoietin / 阿尔法多巴胺（dEPO ）hypoxia-inducible factor stabilizers 缺氧诱导因子稳定剂 (HIF), methoxy polyethylene gl ycol-epoetin beta (CERA)/ 甲氧基聚乙二醇促红细胞生成素- β(CERA) ，(Peginesatide/Hematide) ）； 2. |
男用 Chorionic Gonadotrophin (CG) / 绒促性素（CG ）和 Luteinizing Hormone (LH) /黄体生成素（LH ）； 3． Insulin/胰岛素； 4． Corticotrophins/ 促皮质素 5． Growth hormone （hGH）/生长激素（hGH ）； Insulin-like Growth Factor （IGF-1）/胰岛素样生长因子（如 IGF-1）；Fibroblast Growth Factors (FGFs) /纤维原细胞生长因子(FGFs), Mechano Growth Factors （ MGFs）/机械生长因子（MGF）； Platelet-Derived Growth Factor (PDGF)/ 血小板衍化生长因子(PDGF)； Vascular-Endothelial Gr owth Factor (VEGF) / 脉管内皮细胞生长因子(VEGF) 以及其它肌肉、腱、韧带、蛋白质合成/ 衰变、血管、能量利用、更新能力或纤维组织转化的其他生长因子；以 及其他具有相似化学结构或相似生物作用的物质。 S3. |
B2- 激动剂 所有 b2-激动剂（在适当情况下包括两种光学异构体）均为禁用物质，但沙丁胺醇/salbutamol（24小时内最大剂量为 1600微克）和沙美特罗/ salmeterol 按照制药商建议的治疗方法吸入使用除外。 尿中的沙丁胺醇含量超过 1000 ng/ml 将被推定为不属于有意的治疗用药，因此将被视为阳性检测结果，除非该运 动员能通过受控药代动力学 研究证明此不正常结果确系因使用治疗性沙丁胺醇吸入剂（24 小时内最大剂量为 1600微克）所致。 7 S4. |
荷尔蒙拮抗剂和调节剂 禁用下列类别： 1. |
芳香酶抑制剂，包括但不仅限于：aminogluthetimide/ 氨鲁米特； anastrozole/ 阿那曲唑； androsta-1,4,6-triene-3,17-dione/ 雄甾 1,4,6-三烯 -3,17-二酮(androstatrienedione/ 雄甾三烯二酮 )；4-androstene-3,6,17 trione/ 雄烯 -3,6,17三酮(6-oxo)；exemestane/ 依西美坦； formestane/ 福美坦；letrozole/ 来曲唑； testolactone/ 睾内酯； 2. |
选择性雌激素受体调节器（SERMs ），包括但不仅限于：raloxifene/ 那洛西芬；tamoxifen/ 他莫昔芬；toremifene/托瑞米芬； 3. |
其他抗雌激素作用物质 ，包括但不仅限于： clomiphene/ 氯米芬； cyclofenil/ 环芬尼；fulvestrant/ 氟维司群； 4． 修改肌生成抑制素功能的制剂，包括但不仅限于：肌生成抑制素抑制剂。 S5. |
利尿剂和其他掩蔽剂 禁用掩蔽剂，其中包括： Diuretics/ 利尿剂； desmopressin/ 去氨加压素； plasma expanders/ 血浆膨胀剂（如glycerol/丙三醇，静脉注射 albumin/ 白蛋白 , dextran/ 代血浆 , hydroxyethyl starch/ 羟乙基淀粉和 mannitol/ 甘露醇）；probenecid/ 丙磺舒；以及具有相似生物作用的其它物质。 利尿剂包括： Acetazolamide/ 乙酰唑胺； amiloride/ 阿米洛利； bumetanide/ 布美他尼； canrenone/ 坎利酮；chlortalidone/ 氯噻酮；etacrynic acid/依他尼酸；furosemide/ 呋塞米；indapamide/吲达帕胺；metolazone/ 美托拉宗；spironolactone/ 螺内酯； thiazides （e.g. |
bendroflumethiazide，chlorothiazide ，hydrochlorothiazide ）/噻嗪类 （如苄氟噻嗪、氯噻嗪、氢氯噻嗪）；triamterene/ 氨苯蝶啶；和具有相似化学结构或相似生物作用的其他物质（drosperinone/ 曲螺酮和 pamabrom/ 帕马溴以及局部使用的dorzolamide/和噻吗洛尔 和 brinzolamide/布林佐胺不属于禁用物质，除外）。 8 如可适用，赛内和赛外在服用利尿剂和其他掩蔽剂的同时 ，使用任何剂量有上限规定的物质（如：沙丁胺醇（salbutamol ）、吗啡（morphine ）、去甲伪麻黄碱（cathine ）、麻黄碱（ephedrine ）、甲基麻黄碱（ methylephedrine ）和伪麻黄碱（pseudoephedrine ））除了需要利尿剂和其他掩蔽剂的治疗用药豁免以外，还需获得使用该物质的具体治疗用药豁免。 禁用方法 M1. |
提高输氧能力 禁用以下方法： 1. |
血液兴奋剂，包括使用自体、同源或异源 血液或使用任何来源制成的血红细胞制品。 2. |
人为提高氧气的摄入、流通或释放， 包括但不仅限于使用全氟化合物、efaproxiral （RSR13）及经修饰的血红蛋白制剂（如以血红蛋白为主剂的血液替代品，微囊血红蛋白制剂等），补氧除外。 M2. |
化学和物理篡改 禁用以下方法： 1. |
为改变兴奋剂检查所收集样本的完整性和 合法性，篡改或企图篡改样本。包括但不仅限于：导管插入术及尿样置换和（或）掺杂（如蛋白酶）。 2. |
除了入院和临床分析过程中合理使用外，禁用静脉注射。 3． 禁止循环性抽取全血、将其处理后再注入循环系统。 M3. |
基因兴奋剂 禁止采取下述有可能提高运动成绩的做法： 1. |
移植核酸和核酸序列; 2. |
使用正常细胞和转基因细胞。 9 使用直接或间接作用于已知会影响比赛成绩功能的药剂，如：Peroxisome Proliferator Activated Receptor δ /过氧化体增殖物激活型受体δ (PPAR δ) 兴奋剂 (如 GW 1516) 和 PPARδ-AMP-activated protein kinase/PPAR δ-AMP活化蛋白激酶(AMPK) 中枢兴奋剂( 如 AICAR) 。 赛内禁用物质和方法 除了以上定义的类别 S0至S5，以及 M1至M3外，以下类别在比赛中禁用： 禁用物质 S6. |
刺激剂 禁用所有刺激剂，包括其相关的光学异构体， 但：局部使用的咪唑衍生物以及列入《2011年监控程序》的刺激剂*除外。 刺激剂包括： (a) 非特定物质： Adrafinil/ 阿屈非尼（艾捉非尼）； amfepramone/ 二乙胺苯丙酮； amiphenazole/ 阿米苯唑；amphetamine/ 苯丙胺；amphetaminil/ 安非他尼； benfluorex / 苯氟雷斯；benzphetamine/ 苄非他明；benzylpiperazine/benzylpiperazine ；bromantan/ 布罗曼坦； clobenzorex/ 氯苄雷司； cocaine/可卡因；cropropamide/巴酰丙酰胺； crotetamide/ 巴酰乙酰胺； dimethylamphetamine/ 二甲基苯丙胺（二甲基安非他明）；etilamphetamine/ 乙非他明（乙苯丙胺）； famprofazone/ 泛普法宗； fencamine/ 芬咖明； fenetylline/ 芬乙茶碱；fenfluramine/ 芬氟拉明；fenproporex/ 芬普雷司（氰乙苯丙胺）；furfenorex/ 呋芬雷司（呋甲苯丙胺）； mefenorex/ 美芬雷司（氯丙苯丙胺）； mephentermine/ 美芬丁胺； mesocarb/美索卡（麦索卡）； methamphetamine(d-)/ 甲基苯丙胺(d-) ；p-methylamphetamine/p- 去氧麻黄碱； methylenedioxyamphetamine/ 甲烯二氧苯丙胺； methylenedioxymethamphetamine/甲烯二氧甲苯丙胺； modafinil/ 莫达非尼（莫达芬尼）； norfenfluramine/ 去乙芬氟拉明； phendimetrazine/ 苯甲曲秦（苯双甲吗啉/ 二甲苯吗啉）； phenmetrazine/ 芬美曲秦（苯甲吗啉）； phentermine/ 芬特明（苯丁胺）；4-phenylpiracetam(carphedon)/4-phenylpiracetam（卡非多）；prenylamine/普尼拉明； prolintane/ 普罗林坦（苯咯戊烷）。 10本节未明确列出的刺激剂属于特定物质。 (b) 特定物质（实例） adrenaline**/ 肾上腺素；cathine***/ 去甲伪麻黄碱； ephedrine****/ 麻黄碱；etamivan/香草二乙胺；etilefrine/ 依替福林；fenbutrazate/ 芬布酯；fencamfamin/ 芬坎法明（莰苯乙胺）；heptaminol/ 庚胺醇；isometheptene/ 异美汀；levmetamfetamine/ 左旋甲基苯丙胺； meclofenoxate/ 甲氯芬酯（氯酯醒）； methylephedrine****/ 甲基麻黄碱；methylhexaneamine(dimethylpentylamine) / 甲基已胺（二甲基戊胺） ; methylphenidate/哌醋甲酯； nikethamide / 尼可刹米（尼可刹咪）； norfenefrine/ 去甲苯福林；octopamine/ 奥克巴胺； oxilofrine/ 奥洛福林；parahydroxyamphetamine/ 对羟基苯丙胺；pemoline/ 匹莫林； pentetrazol/ 戊四氮；phenpromethamine/ 苯丙甲胺；propylhexedrine/ 环已丙甲胺；pseudoephedrine/ 伪麻黄碱 *****；selegiline/ 司来吉兰（司立吉林）；sibutramine/ 西布曲明；strychnine/ 士的宁；tuaminoheptane/ 异庚胺，以及其他具有相似化学结构或生物作用的物质。 * 列在 2011年监控程序中的物质（bupropion/ 氨非他酮； caffeine/咖啡因；phenylephrine/脱羟肾上腺素； phenylpropanolamine/ 苯丙羟胺；pipradrol/ 阿扎环醇； synephrine/ 脱氧肾上腺素）不视为禁用物质。 ** 肾上腺素与局麻药合用或局部使用（如鼻，眼等）不属于禁用范围。 **** 尿中去甲伪麻黄碱浓度超过 5 μg/ml 时构成违禁。 ***** 尿中麻黄碱 或甲基麻黄碱浓度超过 10 μg/ml 时构成违禁。 ***** 尿中伪麻黄碱浓度超过 150 μg/ml时构成违禁 。 S7. |
麻醉剂 禁用下列物质： Buprenorphine/ 丁丙诺啡； dextromoramide/ 右吗拉胺（右吗拉米）； diamorphine （heroin）/二醋吗啡（海洛因）；fentanyl and its derivatives/ 芬太尼及其衍生物；hydromorphone/ 氢吗啡酮； methadone/ 美沙酮； morphine/ 吗啡；oxycodone/ 羟考酮；oxymorphone/ 羟吗啡酮；pentazocine/ 喷他佐辛；pethidine/ 哌替啶。 11 S8. |
大麻（酚）类： 天然（如 cannabis 大麻、hashish 哈希什、 marijuana 玛利华纳）或合成 delta 9-tetrahydrocannabinol/delta 9- 四氢大麻醇(THC) 及 cannabimimetics （如含有 JWH018、JWH073 和HU-210的“药料”）禁用。 S9. |
糖皮质类固醇 禁止口服、静脉注射或肌肉注射或直肠给予所有糖皮质类固醇。 特殊项目禁用物质 P1. |
酒精 在下列项目中，酒精（乙醇）仅在赛内禁用。将通过呼吸 气分析和（或）血液进行检查。兴奋剂违规的阈值（血液指标）为 0.10g/L。 · 航空运动（FAI ，国际航空运动联合会） · 射箭（FITA--国际射箭联合会） · 汽车运动（FIA ，国际汽车运动联合会） · 空手道（ WKF，世界空手道联合会） · 摩托车运动（FIM ，国际摩托车运动联合会） · 九瓶和十瓶保龄球（FIQ ，国际保龄球联合会） · 摩托艇（UIM ，国际摩托艇联盟） P2. |
B-阻断剂 下列项目中，除非另有说明，b- 阻断剂仅在赛内禁用。 · 航空运动（FAI ，国际航空运动联合会） · 射箭（FITA--国际射箭联合会）（赛外也禁用） · 汽车运动（FIA ，国际汽车运动联合会） · 台球和斯诺克（ WCBS，世界台球联盟） · 有舵雪橇和钢架雪撬（FIBT ，国际有舵雪橇和平底雪橇联合会） · 滚木球（CMSB－世界滚木球运动联盟） 12· 桥牌（FMB ，世界桥牌联合会） · 冰壶（ WCF，世界冰壶联合会） · 飞镖（ WDF，世界飞镖联合会） · 高尔夫球（IGF ，国际高尔夫球联合会） · 摩托车运动（FIM ，国际摩托车运动联合会） · 现代五项（UIPM ，国际现代五项联盟）（有射击的项目） · 九瓶和十瓶保龄球（FIQ ，国际保龄球联合会） · 摩托艇（UIM, 国际摩托艇联合会） · 帆船（ISAF ，国际帆船运动联合会）（仅对抗赛舵手） · 射击（ISSF ，国际射击联盟）（赛外也禁用） · 滑雪／雪板滑雪（FIS ，国际滑雪联合会）：跳台滑雪、自由式空中技巧／半管和雪板半管／腾空赛 · 摔跤（FILA ，国际业余摔跤联合会） b-阻断剂包括但不仅限于下列物质： Acebutolol/ 醋丁洛尔；alprenolol/ 阿普洛尔（心得舒）；atenolol/ 阿替洛尔；betaxolol/倍他洛尔； bisoprolol/ 比索洛尔； bunolol/布诺洛尔； carteolol/ 卡替洛尔；carvedilol/ 卡维地洛（卡维地罗）；celiprolol/ 塞利洛尔（双胺心安）；esmolol/ 艾司洛尔；labetalol/ 拉贝洛尔（降压乐）；levobunolol/ 左布诺洛尔（左旋丁酮心安）；metipranolol/ 美替洛尔； m etoprolol/ 美托洛尔；nadolol/ 纳多洛尔（羟氢萘心安）；oxprenolol/ 氧烯洛尔； pindolol/吲哚洛尔； propranolol/ 普萘洛尔； sotalol/索他洛尔；timolol/噻吗洛尔。 Resolution 2CP/10 INTERNATIONAL CONVENTION AG AINST DOPING IN SPORT Annex II - Standards for Granting Therapeutic Use Exemptions Paris, 1 January 2011 Extract from the INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS, 1 January 2011 of the World Anti-Doping Agency (WADA) PART TWO: STANDARDS FOR GRANTIN G THERAPEUTIC USE EXEMPTIONS 4.0 Criteria for Granting a Therapeutic Use Exemption A Therapeutic Use Exemption ( TUE ) may be granted to an Athlete permitting the Use of a Prohibited Substance or Prohibited Method . |
An application for a TUE will be reviewed by a Therapeutic Use Exemption Committee ( TUEC ). |
The TUEC will be appointed by an Anti-Doping Organization. |
4.1 A TUE will be granted only in strict accordance with the following criteria: (a) The Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method were to be withheld in the course of treating an acute or chronic medical condition. |
(b) The Therapeutic Use of the Prohibited Substance or Prohibited Method would produce no additional enhancement of perf ormance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. |
The Use of any Prohibited Substance or Prohibited Method to increase “low-normal” levels of any endogenous hormone is not considered an acceptable Therapeutic intervention. |
(c) There is no reasonable Therapeutic alternative to the Use of the otherwise Prohibited Substance or Prohibited Method . |
(d) The necessity for the Use of the otherwise Prohibited Substance or Prohibited Method cannot be a consequence, who lly or in part, of the prior Use, without a TUE , of a substance or method whic h was prohibited at the time of Use. |
4.2 The TUE will be cancelled, if: (a) The Athlete does not promptly comply with any requirements or conditions imposed by the Anti-Doping Organization granting the exemption. |
(b) The term for which the TUE was granted has expired. |
(c) The Athlete is advised that the TUE has been withdrawn by the Anti-Doping Organization. |
(d) A decision granting a TUE has been reversed by WADA or the Court of Arbitration for Sport. |
[Comment: Each TUE will have a specified durati on as decided upon by the TUEC . |
There may be cases when a TUE has expired or has been withdrawn and the Prohibited Substance subject to the TUE is still present in the Athlete’s body. |
In such cases, the Anti-Doping Organization conducting the initial review of an Adverse Analytical Finding will consider whether the finding is co nsistent with expiry or withdrawal of the TUE .] |
4.3 An application for a TUE will not be considered for retroactive approval except in cases where: (a) Emergency treatment or treatment of an acute medical condition was necessary. |
(b) Due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to consider, an application prior to Doping Control . |
[Comment: Medical emergencies or acute me dical situations requiring administration of an otherwise Prohibited Substance or Prohibited Method before an application for a TUE can be made, are uncommon. |
Similarly, circumstances requiring expedited consideration of an application for a TUE due to imminent comp etition are infrequent. |
Anti-Doping Organizations granting TUE s should have internal procedures that permit such situations to be addressed. ] |
5.0. |
Confidentiality of Information 5.1 The collection, storage, processi ng, disclosure and retention of Personal Information in the TUE process by Anti-Doping Organizations and WADA shall comply with the International Standard for the Protection of Privacy and Personal Information . |
5.2 An Athlete applying for a TUE shall provide written consent fo r the transmission of all information pertaining to the application to members of all TUEC s with authority under the Code to review the file and, as required, ot her independent medical or scientific experts, and to all necessary staff involved in the management, review or appeal of TUE s, and WADA . |
The applicant shall also provide written consent for the decision of the TUEC to be distributed to other relevant Anti-Doping Organizations and National Federations under the provisions of the Code . |
[Comment to 5.2: Prior to collecting Personal Information or obtaining consent from an Athlete, the Anti-Doping Organization s hall communicate to the Athlete the information set forth in Article 7.1 of the International Standard for the Protection of Privacy and Personal Information .] |
Should the assistance of external, independent experts be required, all details of the application will be circulated without identifying the Athlete concerned. |
5.3 The members of the TUECs, independent experts and the staff of the Anti-Doping Organization involved, will conduct all of their activ ities in strict confidence and will sign confidentiality agreements. |
In particular, they will keep the following information confidential: (a) All medical information and data provided by the Athlete and physician(s) involved in the Athlete’s care. |
(b) All details of the application including the name of the physician(s) involved in the process. |
Should the Athlete wish to revoke the right of any TUEC to obtain any health information on his/her behalf, the Athlete shall notify his/her medical practitioner in writing of the fact. |
As a conse quence of such a decision, the Athlete will not receive approval for a TUE or renewal of an existing TUE . |
5.4 Anti-Doping Organizations shall ensure that Personal Information obtained in the TUE process is retained for a peri od of eight (8) years, and th ereafter only for as long as necessary to fulfill their obligations under the Code or where otherwise required by applicable law, regulation or compulsory legal process. |
6.0 Therapeutic Use Exemption Committees ( TUEC s) TUEC s shall be constituted and act in acco rdance with the following guidelines: 6.1 TUEC s should include at least three (3) physicians with e xperience in the care and treatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. |
In order to ensure a level of independence of decisions, the majority of the members of any TUEC should be free of conflicts of intere st or political re sponsibility in the Anti- Doping Organization . |
All members of a TUEC will sign a conflict of interest agreement. |
In applications involving Athletes with disabilities, at least one TUEC member shall possess specific experien ce with the care and treatment of Athlete s with disabilities. |
6.2 TUEC s may seek whatever medical or scientif ic expertise they deem appropriate in reviewing the circumstances of any application for a TUE . |
6.3 The WADA TUEC shall be composed following the criteria set out in Article 6.1. |
The WADA TUEC is established to review the granting or denial of TUE s for International-Level Athletes , Athletes entered in an International Event as described under 7.1(b), or Athletes in their National Anti-Doping Organization ’s Registered Testing Pool as set forth in Article 4.4 of the Code . |
In normal circumstances, the WADA TUEC shall render a decision within thirty (30) days of receipt of all requested information. |
7.0 Responsibilities of International Federations and National Anti-Doping Organizations 7.1 Each International Federation shall: (a) Establish a TUEC as provided in Article 6. |
(b) Publish a list of International Events for which a TUE, granted pursuant to the International Federation’s rules, is required. |
(c) Establish and publish a TUE process whereby any Athlete who is in the International Federation’s Registered Testing Pool or who is entered in an International Event described in Article 7.1(b) may request a TUE for a documented medical co ndition requiring the Use of a Prohibited Substance or a Prohibited Method . |
Such a TUE process shall comply with Article 4.4 of the Code , this International Standard and the International Standard for the Protection of Privacy and Personal Information . |
(d) Publish any rule pursuant to which the International Federation will accept TUE s granted by other Anti-Doping Organizations. |
(e) Promptly report to WADA , through ADAMS, the granting of all TUE s, including the approved substance or method, dosage, frequency and route of administration, the duration of the TUE , any conditions imposed in connection with the TUE , and its entire file. |
(f) Promptly report the granting of a TUE to the relevant National Anti-Doping Organization and National Federation. |
(g) At WADA ’s request, promptly provide its entire file on any TUE which has been denied. |
7.2 Each National Anti-Doping Organization shall: (a) Establish a TUEC as provided in Article 6. |
(b) Identify and publish those categories of Athletes within its jurisdiction who are required to obtain a TUE before using a Prohibited Substance or a Prohibited Method. |
At a minimum, this shall include all Athletes in the National Anti-Doping Organization ’s Registered Testing Pool and other national-level Athletes as defined by the National Anti-Doping Organization . |
[Comment to 7.2(b): National Anti-Doping Organizations will not grant TUE s to Athletes in an International Federation’s Registered Testing Pool except in those instances where the Interna tional Federation’s rules r ecognize or give authority to National Anti-Doping Organizations to grant TUE s to such Athletes.] |
(c) Establish and publish a TUE process whereby any Athlete who is in the National Anti-Doping Organization ’s Registered Testing Pool or who is described in 7.2(b) may request a TUE for a documented medical condition requiring the Use of a Prohibited Substance or a Prohibited Method . |
Such a TUE process shall comply with Article 4.4 of the Code , this International Standard and the International Standard for the Protection of Privacy and Personal Information . |
(d) Promptly report to WADA , through ADAMS, the granting of a TUE to any Athlete in its Registered Testing Pool, and if applicable, to an Athlete in an International Federation’s Registered Testing Pool or entered in an International Event described in Article 7.1(b), including th e approved substance or method, dosage, frequency and route of administration, the duration of the TUE , any conditions imposed in connection with the TUE , and its entire file. |
(e) At WADA ’s request, promptly provid e its entire file on any TUE that has been denied. |
(f) Promptly report the granting of a TUE to the relevant National Federation and International Federation where the rules of the International Federation authorize National Anti-Doping Organizations to grant TUE s to International-Level Athletes . |
(g) Recognize TUE s granted by International Federations to Athletes in the International Federation’s Registered Testing Pool or entered in an International Event as described under 7.1(b). |
[As used in this Article 7, the term "pub lish" means: An Anti-Doping Organization shall publish information by providing the information in a conspicuous place on its website and by sending the information to each National Federation which is subject to its rules.] |
8.0 TUE Application Process 8.1 Unless the rules of their International Fe deration provide otherwise, the following Athletes shall obtain a TUE from their International Federation: (a) Athletes in the International Federation’s Registered Testing Pool . |
(b) Athletes participating in an International Event for which a TUE , granted pursuant to the International Federation’s rules, is required. |
8.2 Athletes not identified in Ar ticle 8.1 sha ll obtain a TUE from their National Anti-Doping Organization. |
[Comment to 8.1 and 8.2: Unless the rules of an International Federation provide otherwise, an Athlet e who already has a TUE from a National Anti-Doping Organization, but later becomes a member of the International Federation’s Registered Testing Pool or seeks to participate in an International Event which the International Federation has identified as re quiring an International Federation TUE, shall obtain a new TUE from the International Federation. |
The phrase “unless the rules of an Interna tional Federation provide otherwise” takes into account the fact that some Internat ional Federations, through their rules, are willing to recognize TUEs granted by National Anti-D oping Organizations and do not require a new TUE application at the International Fe deration level. |
Where such rules are in place, the Athlete should obtain a TUE from the Athlete’s National Anti-Doping Organization.] |
8.3 The Athlete should submit an application for a TUE no less than thirty (30) days before he/she needs the approval (for instance, for an Event). |
8.4 A TUE will only be considered following the r eceipt of a completed application form that shall include all relevant documents (see Annex 1 – TUE Form). |
The application process shall be dealt with in accordance with the principles of strict medical confidentiality. |
8.5 The TUE application Form, as set out in Annex 1, can be modified by Anti-Doping Organizations to include additional requests for in formation, but no sections or items shall be removed. |
8.6 The TUE application Form may be tran slated into other languages by Anti-Doping Organizations, but the English or French text shall remain on the application Form. |
8.7 The application shall identify the Athlete’s level of competiti on (e.g., International Federation’s Registered Testing Pool ), sport and, where appropriate, discipline and specific position or role. |
8.8 The application shall list a ny previous and/or current TUE requests, the body to whom the request(s) was made, the decision(s) of that body, and the decision(s) of any other body on review or appeal. |
8.9 The application shall include a comprehens ive medical history and the results of all examinations, laboratory investigations and im aging studies relevant to the application. |
The arguments related to the diagnosis and tr eatment, as well as duration of validity, should be guided by the WADA “Medical Information to Support the Decisions of TUEC s.” 8.10 Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the Anti-Doping Organization before approval will be undertaken at the expense of the applicant. |
[Comment to 8.10: In some cases, the applic ant’s National Federation may elect to pay this expense. ] |
8.11 The application shall include a statemen t by an appropriately qualified physician attesting to the necess ity of the otherwise Prohibited Substance or Prohibited Method in the treatment of the Athlete and describing why an alternative, permitted medication cannot, or could not, be used in th e treatment of this condition. |
8.12 The substance or method, dose, frequency, r oute and duration of administration of the otherwise Prohibited Substance or Prohibited Method in question shall be specified. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.